CO-1686,
rociletinib,
Rociletinib,
1374640-70-6,
CO-1686,
AVL-301,
CNX-419,
CO1686,
CO-1686 (AVL-301),
UNII-72AH61702G,
Rociletinib (CO-1686, AVL-301),
Rociletinib(AVL-301,CNX-419,CO-1686),
72AH61702G,
CO 1686,
N-(3-((2-((4-(4-acetylpiperazin-1-yl)-2-methoxyphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)acrylamide,
N-[3-[[2-[4-(4-acetylpiperazin-1-yl)-2-methoxyanilino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]phenyl]prop-2-enamide,
Rociletinib [USAN:INN],
Tube721,
Rociletinib (USAN/INN),
Rociletinib (CO-1686),
GTPL7966,
SCHEMBL4177736,
CHEMBL3545308,
EX-A228,
C27H28F3N7O3,
BDBM149404,
HMS3653G08,
AOB87314,
BCP07085,
2334AH,
MFCD26793864,
s7284,
ZINC98043800,
AKOS025401943,
AKOS032949985,
CS-1631,
DB11907,
SB16488,
KS-0000062U,
NCGC00386293-08,
4CA-0403,
AC-27467,
AK174788,
AS-17009,
BC600382,
HY-15729,
N-(3-((2-((4-(4-Acetylpiperazin-1-yl)-2-methoxyphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)prop-2-enamide,
QC-11547,
SC-93171,
US8975249, I-4,
FT-0696686,
SW219475-1,
D10858,
A1-04311,
CO-1686|||N-[3-[[2-[4-(4-Acetylpiperazin-1-yl)-2-methoxyanilino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]phenyl]prop-2-enamide,
N-[3-[[2-[[4-(4-Acetyl-1-piperazinyl)-2-methoxyphenyl]amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]phenyl]-2-propenamide,
D0M4AV,
Rociletinib, 98% - 25MG 25mg,
ACN-036292,
A3320,
A13028,
C000589977,
N-[3-[[2-[[4-(4-ethanoylpiperazin-1-yl)-2-methoxy-phenyl]amino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]phenyl]prop-2-enamide,